<DOC>
	<DOCNO>NCT02324543</DOCNO>
	<brief_summary>This study look whether gemcitabine , taxotere , xeloda ( GTX ) combination cisplatin irinotecan effective ( anti-tumor activity ) safe patient metastatic pancreatic cancer .</brief_summary>
	<brief_title>Phase 1/2 Study Gemcitabine/Taxotere/Xeloda ( GTX ) Combination With Cisplatin Irinotecan Subjects With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>The study do 2 part . The first part dose escalation part dose irinotecan increase high safe dose irinotecan define give gemcitabine , taxotere , xeloda , cisplatin . After safe dose irinotecan combination gemcitabine , taxotere , xeloda , cisplatin define , second part use define dos look effective drug advance pancreatic cancer .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Histologically cytologically confirm untreated metastatic pancreatic adenocarcinoma . 2 . Have measurable disease . 3 . Male nonpregnant nonlactating female age &gt; 18 year . 4 . ECOG performance status 0 1 . ECOG 0 indicates patient fully active able carry predisease activity without restriction ; , ECOG 1 indicate patient restrict physically strenuous activity ambulatory able carry work light sedentary nature 5 . Subjects must adequate organ marrow function . 6 . Must use acceptable form birth control prior study duration study . 7 . Willing able comply study procedures 1 . Patient prior chemotherapy within 5 year enrollment . 2 . Patient radiotherapy pancreatic cancer . 3 . Age â‰¥ 76 year 4 . Patient receive receive investigational agent within 28 day prior Day 1 treatment study . 5 . Patient undergone major surgery , diagnostic surgery within 28 day prior Day 1 treatment study . 6 . Patient known brain metastasis . 7 . Patient history hypersensitivity allergic reaction attribute compound similar chemical biologic composition gemcitabine , taxotere , xeloda , cisplatin , irinotecan . 8 . Patient uncontrolled intercurrent illness include , limited , uncontrolled infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement 9 . Patient serious medical risk factor involve major organ system . 10 . Patient known history infection HIV , hepatitis B , hepatitis C. 11 . Pregnant breast feeding . 12 . Patient unwilling unable comply study procedures 13 . Patient clinically significant wound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>